SCHEMBL3584510

SCHEMBL3584510

CCOC(=O)c1cc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n(C)c1-c1cccnc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
MAPT P10636 4/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
CTSB P07858 1/20 0.35
KDM4E B2RXH2 4/20 0.34
HPGD P15428 2/20 0.34
DHODH Q02127 1/20 0.34
ERN1 O75460 1/20 0.34
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TGFBR1 P36897 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28780442 0.88 DHODH (0.43) ALDH1A1MAPTNFKB1MAPK1RAB9A
SCHEMBL3587266 0.84 ALDH1A1 (0.38) ALDH1A1MAPTMAPK1KDM4EHPGD
SCHEMBL1446919 0.84 MAPT (0.36) ALDH1A1MAPTNPC1MAPK1RAB9A
SCHEMBL3581785 0.83 PPIA (0.38) ALDH1A1MAPTNPC1NFKB1MAPK1
SCHEMBL1446969 0.80 ALDH1A1 (0.36) ALDH1A1MAPTKDM4EHPGDLMNA
SCHEMBL3580119 0.80 KDM4E (0.41) ALDH1A1MAPTNPC1RAB9ACTSB
SCHEMBL3583261 0.79 KDM4E (0.40) ALDH1A1MAPTNPC1RAB9ACTSB
SCHEMBL3585030 0.79 TDP2 (0.37) ALDH1A1MAPTNPC1NFKB1MAPK1
SCHEMBL3586613 0.78 ALDH1A1 (0.44) ALDH1A1MAPTNFKB1MAPK1RAB9A
SCHEMBL1447238 0.76 MAPT (0.38) ALDH1A1MAPTNPC1NFKB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
EP-2027091-B1 NEW PHARMACEUTICAL COMPOUNDS BIAL PORTELA & CA SA (PT) 2016-01-06 EP disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 ALDH1A1 1070/4885MAPT 310/4885NPC1 90/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 ALDH1A1 1070/4885MAPT 310/4885NPC1 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.